Rosai-Dorfman disease with primary cutaneous manifestations: report of two cases

© Our Dermatol Online e.2020 e56.1 How to cite this article: Kaddioui Z, El Fetoiki FZ, Hali F, Marnissi F, Dehbi Skali H, Chiheb S. Rosai-Dorfman disease with primary cutaneous manifestations: report of two cases. Our Dermatol Online. 2020;11(e):e56.1-e56.4 Submission: 28.03.2020; Acceptance: 13.07.2020 DOI:10.7241/ourd.2020e.56 Rosai-Dorfman disease with primary cutaneous manifestations: report of two cases


INTRODUCTION
Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy. RDD is a rare benign proliferative disorder of histiocytes in the lymph nodes with occasional extra-nodal involvement of the skin, eyes, nasal cavity, paranasal sinuses, salivary gland, pancreas, skeletal system and central nervous system. The most common site of extranodal involvement is skin, with 10% of the all patients having skin lesions [1]. However, in approximately 3% of the cases, the disease is limited exclusively to the skin [1][2][3][4]. We report 2 cases with RDD, the first patient presented with cutaneous and lymph node involvement, while the other cutaneous only.

Case 1
A 52-year-old patient, presented with a progressive papulo-nodular eruption in the right flank and right gluteal region for 1 year. The lesions were erythematoviolaceous, infiltrated, with mammillated surfaces in places, mesuring 2cm and 9 cm respectively. (Fig. 1). Histological examination with immunohistochemistry showed images of emperipolesis which was S100 positive and CD1a negative (Fig. 2).
A PET scan, revealed polyadenopathies in the basicervical region, the mediastinum and the hiles with hypermetabolism. The anti-nuclear antibodies (ANA) was positive. The patient was treated with thalidomide 100 mg/day, in the absence of improvement, methotrexate at a dose of 25 mg/week was started with a slight improvement. The management was completed by excision of the cutaneous lesions with a good evolution and the addition of a oral corticosteroid 1 mg/kg/day (Fig 3). The patient is stable until now.

Case 2
A 47-year-old woman, had for 1 year, 2 nodular lesions on an erythematous plaque in her back. The clinical examination found two erythematous nodules, with presence of satellites papular lesions (Fig. 4). The histological study with IHC confirmed the diagnosis. Laboratory tests and radiologic assessement were negative. For esthetic reason and the significant size of the lesion, a super high potency topical corticosteroids was used with partial regression.

DISCUSSION
RDD has mainly 2 forms: one affecting lymph nodes and rarely other organs with systemic manifestations and the other purely cutaneous form without systemic or nodal disease, even with long-term follow-up [5,6]. This case reports presents the two forms.
The exact etiology of systemic and cutaneous Rosai-Dorfman disease is unknown, but in many case reports and small studies, the laboratory findings suggest an immune dysfunction to an antigen or infectious organism. The most frequently described infections are human herpes virus (HHV6) infection [1,7], Epstein-Barr virus [8], infection, HIV positivity [8], varicella and herpes zoster [9], RDD has also been associated with immune abnormalities including uveitis [10], systemic lupus erythematosus [11] and autoimmune haemolytic anaemia [12] in some patients.
Most common site of cutaneous involvement is the facial area, followed by trunk, ear, neck, upper and lower extremities, and genitals [13,14].
Clinical features are usually characterized by the combination of papules, plaques, or nodules and pustules, granuloma annulare-like, psoriasiform, rosacea-like, xanthelasma-like, acneiform, vasculitislike, and pseudotumor-like lesions [6,8,15,16]. One of the most common type of lesions is central nodulo plaque with surrounding satellite papules. Skin discoloration is also seen with erythematous brownish, gray-blue, violaceous, or yellowish hue appearance.    Ulceration, superficial scaling, or infiltration of lesions into deeper dermis can cause functional or esthetic problems. In our cases, the first one had papulo-nodular eruption erythemato-violaceous and the second one two erythematous nodules, with presence of satellites papular lesions.
Systemic symptoms (fever, malaise), anaemia, raised erythrocyte sedimentation rate (ESR) and immunological abnormalities commonly seen in systemic RDD. Systemic form of the disease principally affects children and young adults with a median age at onset of 20.6 years, whereas cutaneous form is more common in elderly women, with a median age at onset of 43.5 years. People of white ethnicity and Asians are dominantly affected [13,14]. Our first patient is medium brown skin and male with positive ANA test.
Lymph node involvement alone is found in 57% of patients. Multiple, painless cervical lymphadenopathy is the most frequent initial symptom of the disease, seen in almost 90% of the cases [17]. In our patients, there was no palpable lymphadenopathy but detected in first cas during imaging studies .
The definitive diagnosis of pure cutaneous RDD requires histological examination. Histological findings in cutaneous RDD are similar in all involved locations. This is characterized by dense histiocytic infiltrates with plasma cells and lymphocytes. The large histiocytes (Rosai-Dorfman cells) have vesicular nuclei with indistinct cell borders. They exhibit the phenomenon of emperipolesis. These histiocytes are strongly reactive for S-100 protein and variably positive for CD68 but are negative for CD1a. In both patients, RDD was confirmed by histological study with immunohistochemistry The clinical course of RDD is usually benign and selflimited, especially in those presenting with localized lymph node involvement. For most cases, no treatment is necessary as spontaneous resolution is observed over 1-3 years [18]. We treat if the lesions persist for longer periods of time or the are cosmetically unacceptable.
The optimal duration of steroids or other systemic therapies for RDD is not known. Six to 12 months of systemic therapy followed by observation, assuming tolerance and a favourable response to treatment, is a reasonable approach [19]. Data are insufficient to characterize the prognosis of RDD in great detail.
Patients with multifocal and extranodal RDD, particularly those with kidney, liver or lower respiratory tract disease, appear to have an unfavorable prognosis. One of our patients received systemic corticosteroid therapy because he had cutaneous and lymph node involvement , and the second was treated with topical corticosteroids because he had just a cutaneous RDD. They are still being followed with good evolution.